Statement Of Cash Flows [Abstract]

Optomed Oyj - Filing #2160892

Concept	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	4,441,000 EUR	—	4,441,000 EUR	—	5,472,000 EUR	5,472,000 EUR	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories	118,000 EUR	—	—	—	68,000 EUR	—	—
Other adjustments for non-cash items	289,000 EUR	—	—	—	770,000 EUR	—	—
Cash flows from (used in) operations	354,000 EUR	—	—	—	2,171,000 EUR	—	—
Interest paid, classified as operating activities	169,000 EUR	—	—	—	76,000 EUR	—	—
Cash flows from (used in) operating activities	615,000 EUR	—	—	—	2,370,000 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities	213,000 EUR	—	—	—	780,000 EUR	—	—
Purchase of intangible assets, classified as investing activities	2,199,000 EUR	—	—	—	2,249,000 EUR	—	—
Cash flows from (used in) investing activities	2,412,000 EUR	—	—	—	3,029,000 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	4,310,000 EUR	—	—	—	9,012,000 EUR	—	—
Repayments of borrowings, classified as financing activities	1,921,000 EUR	—	—	—	912,000 EUR	—	—
Payments of lease liabilities, classified as financing activities	462,000 EUR	—	—	—	415,000 EUR	—	—
Cash flows from (used in) financing activities	1,609,000 EUR	—	—	—	7,003,000 EUR	—	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	1,419,000 EUR	—	—	—	1,605,000 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	13,000 EUR	—	—	—	115,000 EUR	—	—
Cash and cash equivalents	—	7,118,000 EUR	—	8,524,000 EUR	—	—	6,804,000 EUR